KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms

KalVista Pharmaceuticals, Inc.

Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.
1,702 patient start forms received in US through Feb 2026, nearly 20% of HAE population; 724 unique prescribers activated.
R&D expenses $33.4M (down from $52.2M YoY); SG&A $124.7M (up from $64.9M) due to commercialization costs.
Cash, equivalents and marketable securities $300.2M as of Dec 31, 2025; company expects to fund through profitability.
Pediatric Phase 3 KONFIDENT-KID trial fully enrolled; interim data to be presented at 2026 Global Angioedema Summit; NDA filing planned Q3 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KalVista Pharmaceuticals, Inc. reported the eight months ended December 31, 2025 results: revenue $49.1 million global net product revenue.

Period: the eight months ended December 31, 2025
Revenue: $49.1 million global net product revenue
Result: reported results

Exact text from the filing

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update $49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-122784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.